Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03927105
Title Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Big Ten Cancer Research Consortium
Indications

peripheral T-cell lymphoma

Therapies

Cabiralizumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
Unviersity of Wisconsin Madison Wisconsin 53705 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field